English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Patients who have undergone organ transplantation can present with a variety of oral lesions that appear to be related either directly to their medication or arise as a consequence of drug-induced immunosuppression. Such lesions are commonly caused by fungal and viral agents. CampathTM (Alemtuzumab, a B and T cell depleting monoclonal antibody against CD-52) is used in cardiac transplant patients with refractory rejection. The profound T-cell suppression that occurs with CampathTM therapy broadens the differential diagnosis for such lesions to include potentially severe etiologies typically considered in patients with HIV. This report reviews the causes of oral lesions in immunosuppressed patients, specifically in the context of CampathTM therapy and describes an unusual case of a benign cause of a new oral lesion, chronic biting of the oral mucosa or Morsicato mucosae in a pediatric heart transplant recipient who was treated with CampathTM for cardiac allograft rejection.

A New White Oral Lesion in a Pediatric Heart Transplant Recipient Following Campath™ Therapy: Expanding the Differential Diagnosis